Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck (MRK) to $98 from $99 and keeps an Equal Weight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Verona Pharma downgraded to Hold from Buy at Truist
- Merck’s doravirine/islatravir NDA in HIV-1 accepted by FDA
- Merck & Company’s Strategic Acquisition of Verona Pharma: Balancing Long-Term Gains with Short-Term Financial Adjustments
- Merck’s Strategic Acquisition of Verona Pharma: Enhancing Respiratory Portfolio Amidst Keytruda Competition
- Verona Pharma Stock (VRNA) Soars 20% on $10B Merck Deal